The eukaryotic translation initiation factor 4E (eIF4E) is dysregulated in a wide variety of cancers. Higher expression of eIF4E promotes tumorigenesis and has been implicated in cancer development and progression. Regulation of eIF4E is particularly controlled through phosphorylation yielding phospho-eIF4E (p-eIF4E). p-eIF4E is a signaling molecule that participates in several pathways, including regulating various cancer-related processes. The role of phosphorylation of eIF4E at Serine 209 on oncogenic transformation has been appreciated for the last 10 years and has been under active investigation as a therapeutic target for cancers including acute myeloid leukemia (AML), but the expression of p-eIF4E in the nucleus and the specific molecular mechanism of action remain largely unresolved. It is selectively and highly expressed in AML where its expression was associated with poor outcomes and prognosis. The purpose of this review is to describe p-eIF4E as an indicator prognosis and a potential anticancer target for biological therapy of AML.

真核翻译起始因子 4E (eIF4E) 在多种癌症中失调。 eIF4E 的较高表达会促进肿瘤发生，并与癌症的发生和进展有关。 eIF4E 的调节特别是通过产生磷酸化 eIF4E (p-eIF4E) 的磷酸化来控制。 p-eIF4E 是一种信号分子，参与多种途径，包括调节各种癌症相关过程。 eIF4E 在丝氨酸 209 上的磷酸化对致癌转化的作用在过去 10 年中得到了重视，并且作为包括急性髓系白血病 (AML) 在内的癌症的治疗靶点一直在积极研究中，但 p-eIF4E 在细胞核中的表达并且具体的作用分子机制在很大程度上仍未解决。它在 AML 中选择性且高度表达，其表达与不良结果和预后相关。本综述的目的是将 p-eIF4E 描述为 AML 生物治疗的预后指标和潜在抗癌靶点。